ResearchMoz

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

GBI Research
Published Date » 2014-08-21
No. Of Pages » N/A
 GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Introduction
2.1 Disease Introduction
2.2 Classification of Brain Tumors
2.3 Tumor Grading
2.4 Subtypes of Glioblastoma Multiforme
2.5 Etiology
2.6 Pathophysiology
2.6.1 Loss of Heterozygosity of Chromosome 10
2.6.2 Epidermal Growth Factor Receptor Amplification
2.6.3 Phosphatase and Tensin Homolog Mutation
2.6.4 Loss of p53 Function
2.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function
2.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation
2.7 Symptoms
2.8 Diagnosis
2.9 Prognosis
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Surgery
2.11.2 Radiation Therapy
2.11.3 Chemotherapy
2.11.4 Targeted Therapy
2.11.5 Drugs for Symptom Relief
2.11.6 Other Alternative Therapies
2.12 Treatment Algorithm
2.13 GBI Research Report Guidance

3 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products
3.1 Key Marketed Products
3.2 Temodar (temozolomide) – Merck
3.3 Avastin (bevacizumab) – Roche
3.4 BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan)
3.4.1 BiCNU (carmustine) – Bristol-Myers Squibb
3.4.2 Gliadel Wafer (carmustine in polifeprosan) – Eisai
3.5 Unlicensed/Off-Label Use in Glioblastoma Multiforme
3.5.1 Lomustine
3.5.2 Carboplatin
3.5.3 Teniposide
3.6 Comparative Efficacy and Safety
3.7 Unmet Needs

4 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Pipeline
4.1 Overall Pipeline
4.2 Molecular Targets
4.3 Clinical Trials
4.3.1 Clinical Trial Size
4.3.2 Clinical Trial Duration
4.3.3 Failure Rate of Developmental Pipeline
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Pipeline Candidates
4.4.1 Rindopepimut (CDX-110) – Celldex Therapeutics
4.4.2 Avastin (bevacizumab) – Roche
4.4.3 Cotara – Peregrine Pharmaceuticals
4.4.4 BIOMAb (nimotuzumab) – BioCon
4.5 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Glioblastoma Multiforme Pipeline

5 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Market Forecast to 2020
5.1 Asia-Pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 India
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Glioblastoma Multiforme Therapeutics in the Asia-Pacific Market to 2020
5.6.1 Drivers
5.6.2 Barriers

6 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations
6.1 Major Co-Development Deals
6.1.1 Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical
6.1.2 Immatics Biotechnologies Enters into Agreement with Cancer Research UK
6.2 Major Licensing Deals
6.2.1 Eisai Received Marketing Authorization Holder License with Nobelpharma for Gliadel in Japan
6.2.2 Teva Pharma Enters into Agreement with Perrigo for Generic Temozolomide
6.2.3 SOM Biotech Enters into Licensing Agreement with Argon Pharma for SOM0777
6.2.4 ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania
6.2.5 Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children’s Hospital Medical Center
6.2.6 Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center

7 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 All Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 Phase I
7.4.4 Phase II
7.4.5 Phase III and Pre-Registration
7.4.6 Undisclosed stage of development
7.5 Market Forecasts to 2020
7.5.1 Asia-Pacific
7.5.2 Australia
7.5.3 China
7.5.4 India
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Therapeutic Landscape
7.6.4 Forecasting
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Competitive Landscape
7.8 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer

List of Tables

Table 1: Glioblastoma Multiforme, Classification of Brain Tumors by the American Association of Neurological Surgeons, 2014
Table 2: Glioblastoma Multiforme, World Health Organization Classification of Glioma, 2005
Table 3: Glioblastoma Multiforme, Karnofsky Performance Status Score (%), 1984
Table 4: Discovery
Table 5: Preclinical and IND/CTA-filed
Table 6: Phase I
Table 7: Phase II
Table 8: Phase III and pre-registration
Table 9: Undisclosed stage of development
Table 10: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Forecast Data, 2013–2020
Table 11: Glioblastoma Multiforme Therapeutics, Australia, Forecast Data, 2013–2020
Table 12: Glioblastoma Multiforme Therapeutics, China, Forecast Data, 2013–2020
Table 13: Glioblastoma Multiforme Therapeutics, India, Forecast Data, 2013–2020
Table 14: Glioblastoma Multiforme Therapeutics, Japan, Forecast Data, 2013–2020

List of Figures

Figure 1: Glioblastoma Multiforme, Genetic Pathways to Primary and Secondary GBM and the Incidence of Mutations, 2014
Figure 2: Glioblastoma Multiforme, Treatment Algorithm for Glioblastoma Multiforme, 2014
Figure 3: Glioblastoma Multiforme, Treatment Options for Recurrent Glioblastoma Multiforme, 2014
Figure 4: Glioblastoma Multiforme, Global, Historical Sales of Temodar ($m), 2008–2013
Figure 5: Glioblastoma Multiforme, Global, Historical Sales of Avastin ($bn), 2004–2013
Figure 6: Glioblastoma Multiforme, Global, Historical Sales of Gliadel Wafer ($m), 2003–2006
Figure 7: Glioblastoma Multiforme , Global, Heat Map for Marketed Products, 2013
Figure 8: Glioblastoma Multiforme, Global, Overall Pipeline, 2013
Figure 9: Glioblastoma Multiforme, Global, Program Type by Phase and Molecular Targets, 2013
Figure 10: Glioblastoma Multiforme, Global, Mean Clinical Trial Size by Molecule Type, 2006–2013
Figure 11: Glioblastoma Multiforme, Global, Mean Clinical Trial Duration by Molecule Type (Months), 2006–2013
Figure 12: Glioblastoma Multiforme, Global, Clinical Trial Failure Rate by Phase by Molecule Type and Reasons for Failure, 2006–2013
Figure 13: Glioblastoma Multiforme, Asia-Pacific, Heat Map for Pipeline Products, 2013
Figure 14: Glioblastoma Multiforme, Asia-Pacific, Product Competitiveness Framework, 2013
Figure 15: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Treatment Use Patterns (‘000), 2013–2020
Figure 16: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Market Size ($m), 2013–2020
Figure 17: Glioblastoma Multiforme Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020
Figure 18: Glioblastoma Multiforme Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020
Figure 19: Glioblastoma Multiforme Therapeutics, Australia, Market Size ($m), 2013–2020
Figure 20: Glioblastoma Multiforme Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020
Figure 21: Glioblastoma Multiforme Therapeutics, China, Annual Cost of Therapy ($), 2013–2020
Figure 22: Glioblastoma Multiforme Therapeutics, China, Market Size ($m), 2013–2020
Figure 23: Glioblastoma Multiforme Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020
Figure 24: Glioblastoma Multiforme Therapeutics, India, Annual Cost of Therapy ($), 2013–2020
Figure 25: Glioblastoma Multiforme Therapeutics, India, Market Size ($m), 2013–2020
Figure 26: Glioblastoma Multiforme Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020
Figure 27: Glioblastoma Multiforme Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 28: Glioblastoma Multiforme Therapeutics, Japan, Market Size ($m), 2013–2020

Upcoming Reports:

Poland: carrots and turnips market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the carrots and turnips market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the carrots and turnips market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...
Poland: steel household products market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the steel household products market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the steel household products market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
ENT And Bronchoscopy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
ENT (Ear, Nose and Throat) and Bronchoscopy devices market comprises of a wide array of medical devices such as ENT powered instruments and radiofrequency devices, ENT hand instruments, endoscopes, bronchial stents, bronchial flexible scope and airway stents. These devices are used in a number of surgical procedures and treatment associated with ENT and lung diseases such as myringotomy, stapedectomy, tonsillectomy, internal biopsy and bronchial stenting. These surgical procedures are used in the treatment of a variety of diseases such as acute oitis media, eustachian tube...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...